Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 54 min ago
Peer-reviewedLicence not statedJAMA

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer

  • HARMONi-A Study Investigators
  • Wenfeng Fang1
  • Yuanyuan Zhao1
  • Yongzhong Luo2
  • Runxiang Yang3
  • Y Huang1
  • Zhiyong He4
  • Hongyun Zhao1,5
  • Mengxia Li6,7
  • K P Li8
  • Qibin Song9
  • Xiaobo Du10
59 more authors
  • Yulan Sun11
  • Wei Li12,13,14
  • Longhua Sun15
  • Zhiyu Wang12,16
  • Kunning Yang17
  • Yun Fan18
  • Baogang Liu19
  • Hongyun Zhao1,5
  • Ying Hu20
  • Li Jia21
  • Xu Shen22
  • Tienan Yi23
  • Dongqing Lv24
  • Haitao Lan25
  • Mengxia Li6,7
  • Wenhua Liang26
  • Yongsheng Wang27,28
  • Hui Yang29
  • Yuming Jia30
  • Yuan Chen31,32
  • Junguo Lu33
  • Meiqi Shi34
  • Chunling Liu35
  • Ming Zhou36
  • Jianya Zhou37
  • Xin Liu38
  • Ningning Zhou1
  • Ming He16
  • Xiaorong Dong39
  • Hualin Chen40
  • Yongxing Chen31,32
  • Haichuan Su
  • X J Li
  • Zhihong Zhang
  • Lei Yang
  • Ying Liu
  • Likun Chen1
  • Xue Hou1
  • Yu Zhang
  • Jun Guo
  • Ruiqiang Ma
  • Hong Lu
  • Di Wu
  • 冯卫能
  • Wen Li12,13,14
  • Jianan Huang
  • Yan Wang27,28
  • Xia Song

60 listed; 71 in total.

40 affiliations
  1. 1Sun Yat-sen University Cancer Center, Guangzhou, China
  2. 2Hunan Cancer Hospital, Changsha, China
  3. 3The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital), Kunming, China
  4. 4Fujian Provincial Tumor Hospital, Fuzhou, China
  5. 5The Second Hospital of Anhui Medical University, Hefei, China
  6. 6Army Medical Center of the Chinese People’s Liberation Army, Chongqing, China
  7. 7The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  8. 8Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
  9. 9Renmin Hospital of Wuhan University, Wuhan, China
  10. 10Mianyang Central Hospital, Mianyang, China
  11. 11Shandong Cancer Prevention and Treatment Institute, Jinan, China
  12. 12Akeso Biopharma Inc, Zhongshan, China
  13. 13The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
  14. 14The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
  15. 15The First Affiliated Hospital of Nanchang University, Nanchang, China
  16. 16The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
  17. 17Weifang No. 2 People’s Hospital, Weifang, China
  18. 18Zhejiang Cancer Hospital, Hangzhou, China
  19. 19Harbin Medical University Cancer Hospital, Harbin, China
  20. 20Beijing Chest Hospital, Capital Medical University, Beijing, China
  21. 21Yuncheng Central Hospital of Shanxi Province, Yuncheng, China
  22. 22Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, China
  23. 23Xiangyang Central Hospital, Xiangyang, China
  24. 24Taizhou Municipal Hospital, Taizhou, China
  25. 25Sichuan Provincial People’s Hospital, Chengdu, China
  26. 26The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China
  27. 27General Hospital of Ningxia Medical University, Yinchuan, China
  28. 28West China Hospital of Sichuan University, Chengdu, China
  29. 29The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China
  30. 30Yibin Second People’s Hospital, Yibin, China
  31. 31Hainan General Hospital, Haikou, China
  32. 32Tongji Hospital of Tongji Medical College of Hust, Wuhan, China
  33. 33Nantong Tumor Hospital, Nantong, China
  34. 34Jiangsu Cancer Hospital, Nanjing, China
  35. 35Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China
  36. 36Affiliated Cancer Hospital and Institution of Guangzhou Medical University, Guangzhou, China
  37. 37The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
  38. 38The Second Xiangya Hospital of Central South University, Changsha, China
  39. 39Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
  40. 40Affiliated Hospital of Guangdong Medical University, Guangzhou, China
Open at sourceDOICite

Related

  1. PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study
    Wenjun Liao, Qiaohua Li, Yue Deng +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  2. Anti‐PD‐1/CTLA‐4 bispecific antibody‐based combination therapy for cervical cancer: a multicenter study with biomarker analysis
    Jiwei Li, Yuping Deng, Tao Wu +4
    Frontiers in immunologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  3. Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3–Directed and PSMA-Directed Bispecific Antibody–Drug Conjugate, for the Treatment of Prostate Cancer
    Yao Xu, Fu Li, Zhiyu Cui +15
    Molecular Cancer TherapeuticsPeer-reviewedCC BY-NC-ND 4.0Full text1 citedOncologyPMC
  4. EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study
    Ting Xu, Christine M. Parseghian, Yanqiao Zhang +15
    Clinical Cancer ResearchPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  5. Immunizing small cell lung cancer mice with isoaspartylated Elavl4 after chemotherapy mimics improved survival of anti-ELAVL4 antibody-positive small cell lung cancer patients
    D. A. Velarde, J. A. Valdes, H. Lee +10
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{investigators2026bispecific,
  title = {{Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer}},
  author = {HARMONi-A Study Investigators and Wenfeng Fang and Yuanyuan Zhao and Yongzhong Luo and Runxiang Yang and Y Huang and Zhiyong He and Hongyun Zhao and Mengxia Li and K P Li and Qibin Song and Xiaobo Du and Yulan Sun and Wei Li and Longhua Sun and Zhiyu Wang and Kunning Yang and Yun Fan and Baogang Liu and Hongyun Zhao and Ying Hu and Li Jia and Xu Shen and Tienan Yi and Dongqing Lv and Haitao Lan and Mengxia Li and Wenhua Liang and Yongsheng Wang and Hui Yang and Yuming Jia and Yuan Chen and Junguo Lu and Meiqi Shi and Chunling Liu and Ming Zhou and Jianya Zhou and Xin Liu and Ningning Zhou and Ming He and Xiaorong Dong and Hualin Chen and Yongxing Chen and Haichuan Su and X J Li and Zhihong Zhang and Lei Yang and Ying Liu and Likun Chen and Xue Hou and Yu Zhang and Jun Guo and Ruiqiang Ma and Hong Lu and Di Wu and 冯卫能 and Wen Li and Jianan Huang and Yan Wang and Xia Song},
  journal = {JAMA},
  year = {2026},
  month = jun,
  doi = {10.1001/jama.2026.7745},
  url = {https://pubmed.ncbi.nlm.nih.gov/42307937/},
}
RIS
TY  - JOUR
TI  - Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
AU  - HARMONi-A Study Investigators
AU  - Wenfeng Fang
AU  - Yuanyuan Zhao
AU  - Yongzhong Luo
AU  - Runxiang Yang
AU  - Y Huang
AU  - Zhiyong He
AU  - Hongyun Zhao
AU  - Mengxia Li
AU  - K P Li
AU  - Qibin Song
AU  - Xiaobo Du
AU  - Yulan Sun
AU  - Wei Li
AU  - Longhua Sun
AU  - Zhiyu Wang
AU  - Kunning Yang
AU  - Yun Fan
AU  - Baogang Liu
AU  - Hongyun Zhao
AU  - Ying Hu
AU  - Li Jia
AU  - Xu Shen
AU  - Tienan Yi
AU  - Dongqing Lv
AU  - Haitao Lan
AU  - Mengxia Li
AU  - Wenhua Liang
AU  - Yongsheng Wang
AU  - Hui Yang
AU  - Yuming Jia
AU  - Yuan Chen
AU  - Junguo Lu
AU  - Meiqi Shi
AU  - Chunling Liu
AU  - Ming Zhou
AU  - Jianya Zhou
AU  - Xin Liu
AU  - Ningning Zhou
AU  - Ming He
AU  - Xiaorong Dong
AU  - Hualin Chen
AU  - Yongxing Chen
AU  - Haichuan Su
AU  - X J Li
AU  - Zhihong Zhang
AU  - Lei Yang
AU  - Ying Liu
AU  - Likun Chen
AU  - Xue Hou
AU  - Yu Zhang
AU  - Jun Guo
AU  - Ruiqiang Ma
AU  - Hong Lu
AU  - Di Wu
AU  - 冯卫能
AU  - Wen Li
AU  - Jianan Huang
AU  - Yan Wang
AU  - Xia Song
PY  - 2026
DA  - 2026/06/17
JO  - JAMA
DO  - 10.1001/jama.2026.7745
UR  - https://pubmed.ncbi.nlm.nih.gov/42307937/
SN  - 0002-9955
SN  - 0098-7484
SN  - 1538-3598
SN  - 2376-8118
ER  -